Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	29.10B
Revenue (ttm)	11.81B
Net Income (ttm)	2.06B
Shares Out	894.67M
EPS (ttm)	2.24
PE Ratio	16.09
Forward PE	14.53
Dividend	1.10 (3.05%)
Ex-Dividend Date	Jul 8, 2024

Volume	11,602,991
Average Volume	5,158,300
Open	34.87
Previous Close	35.44
Day's Range	34.87 - 36.48
52-Week Range	34.07 - 44.72
Beta	0.27
RSI	62.91
Earnings Date	Mar 27, 2025

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2024, SHE:000513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.